Literature DB >> 3246571

Toxic effects of topically administered Betagan, Betoptic, and Timoptic on regenerating corneal epithelium.

G E Trope1, G S Liu, P K Basu.   

Abstract

Re-epithelialization of 40 iatrogenic cornea ulcers produced in rabbits with iodine vapour burn were studied after topical administration of Betagan, Betoptic or Timoptic. At 24 hours there was no statistical difference in the wound healing rates among all the treated animal groups. At 48 hours, all the drug-treated groups were significantly different from the control group (p less than 0.05). There was no difference between the Betagan and Betoptic treated groups but the Timoptic-treated group was slower (p less than 0.05) than the Betoptic treated group, while the difference between the Timoptic and Betagan treated groups is not significant. At 72 hours the re-epithelialization rate of the Timoptic treated group was significantly slower than both the Betagan and Betoptic treated groups (p less than 0.05). By the 16th day following ulceration SEM examination revealed the Timoptic treated group had extensive epithelial cell desquamation, as well as hole formation and plasma membrane disruption. The Betagan treated corneas had mild superficial epithelial changes with loss of microvilli or slight desquamation. The Betoptic treated corneas were completely healed. In conclusion, Betagan is less toxic than Timoptic. Betoptic is the least toxic of the three drugs to regenerating rabbit corneal epithelium.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3246571     DOI: 10.1089/jop.1988.4.359

Source DB:  PubMed          Journal:  J Ocul Pharmacol        ISSN: 8756-3320


  11 in total

1.  Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone.

Authors:  J Shimazaki; K Hanada; Y Yagi; J Yamagami; M Ishioka; S Shimmura; K Tsubota
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

Review 2.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

3.  Effect of topical beta blockers on corneal epithelial wound healing in the rabbit.

Authors:  J J Reidy; J Zarzour; H W Thompson; R W Beuerman
Journal:  Br J Ophthalmol       Date:  1994-05       Impact factor: 4.638

Review 4.  Corneal epithelial wound healing.

Authors:  H S Dua; J A Gomes; A Singh
Journal:  Br J Ophthalmol       Date:  1994-05       Impact factor: 4.638

Review 5.  Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  M M Buckley; K L Goa; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

6.  Early conjunctival changes following treatment with metipranolol and preservatives are not reversible with dexamethasone.

Authors:  H Mietz; U Schlötzer-Schrehardt; J H Lemke; G K Krieglstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-07       Impact factor: 3.117

Review 7.  Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.

Authors:  A M Brooks; W E Gillies
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

8.  Activation of ADRB2/PKA Signaling Pathway Facilitates Lipid Synthesis in Meibocytes, and Beta-Blocker Glaucoma Drug Impedes PKA-Induced Lipid Synthesis by Inhibiting ADRB2.

Authors:  Ikhyun Jun; Young Joon Choi; Bo-Rahm Kim; Kyoung Yul Seo; Tae-Im Kim
Journal:  Int J Mol Sci       Date:  2022-08-22       Impact factor: 6.208

9.  Effect of latanoprost and timolol on the histopathology of the human conjunctiva.

Authors:  N Terai; U Schlötzer-Schrehardt; J Lampel; A G Böhm; C Rummelt; E Schmidt; L E Pillunat
Journal:  Br J Ophthalmol       Date:  2008-10-29       Impact factor: 4.638

Review 10.  Advanced drug delivery and targeting technologies for the ocular diseases.

Authors:  Jaleh Barar; Ayuob Aghanejad; Marziyeh Fathi; Yadollah Omidi
Journal:  Bioimpacts       Date:  2016-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.